Introduction. Well-known the fact that obesity, especially its abdominal (visceral) form, is one of the most important risk factors for hypertension.
The purpose: to determine the level of adiponutrin in patients with hypertension and obesity. Assess how the degree of hypertension and obesity affects the level of adiponutrin in our patients with this comorbid pathology.
Materials and methods. The study included 58 patients with hypertension. Grade 1 was diagnosed in 12 (20.69%), grade 2 - in 16 (27.59%), grade 3 - in 30 (51.72%) examined patients. Of these, 32 women and 26 men aged 32 to 79 years (mean age 57.5 ± 10.11 years). Patients underwent anthropometric measurements, assessed lipid profile and changes in carbohydrate metabolism, adiponutrin levels.
Results. The level of adiponutrin in all groups of hypertensive patients with overweight and obesity was significantly increased compared to the control group, but the degree of hypertension did not affect the level of adiponutrin. However, the concentration of the latter in the serum gradually increases according to the duration of hypertension. In addition, the level of adiponutrin increased depending on the degree of obesity, which, in turn, was confirmed by a reliable direct linear relationship between adiponutrin and body mass index.
Conclusions. Based on the data obtained, adiponutrin can be considered as a marker of metabolic syndrome.
GBD 2017 Risk Factor Collaborators (2018). Global, regional, and national comparative riskassessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England), 392(10159), 1923. doi: 10.1016/S0140-6736(18)32225-6.
Afshin, A., Forouzanfar, M. H., Sur, P., Estep, K., & Lee, A. (2017). Health effects of overweightand obesity in 195 countries over 25 years. GBD 2015 Obesity Collaborators. N Engl J Med, 377, 13–27. doi: 10.1056/NEJMoa1614362.
WHO. World Health Organization. 2016. ProMED-mail website. Retrieved from: http://www.who.int/mediacentre/factsheets/fs311/en/
Bluher, M. (2020). Metabolically healthy obesity. Endocrine Reviews, 41(3), 405–420. doi: 10.1210/endrev/bnaa004.
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., Toplak, H. (2015). Europeanguidelines for obesity management in adults. Obesity facts, 8(6), 402–424. doi: 10.1159/000442721.
Hauner, H., Woodward, E. (2016). Looking Back-EASO Is Celebrating Its 30th Anniversary. Obesityfacts, 9(5), 363–364. doi: 10.1159/000452647.
Bray, G. A., Kim, K. K., Wilding, J. P. H., on behalf of the World Obesity Federation. (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews, 18(7), 715–723. doi: 10.1111/obr.12551.
Winberg, M. E., Motlagh, M. K., Stenkula, K. G., Holm, C., Jones, H. A. (2014). Adiponutrin: amultimeric plasma protein. Biochemical and biophysical research communications, 446(4), 1114–1119. doi: 10.1016/j.bbrc.2014.03.078.
Huang, Y., He, S., Li, J. Z., Seo, Y. K., Osborne, T. F., Cohen, J. C., Hobbs, H. H. (2010). A feedforward loop amplifies nutritional regulation of PNPLA3. Proceedings of the National Academy of Sciences, 107(17), 7892–7897. doi: 10.1073/pnas.1003585107.
Pingitore, P., Pirazzi, C., Mancina, R. M., Motta, B. M., Indiveri, C., Pujia, A., Montalcini, T.,Hedfalk, K., Romeo, S. (2014). Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1841(4), 574–580. doi: 10.1016/j.bbalip.2013.12.006.
Pirazzi, C., Valenti, L., Motta, B. M., Pingitore, P., Hedfalk, K., Mancina, R. M., ... & Maglio, C.(2014). PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human molecular genetics, 23(15), 4077–4085. doi: 10.1093/hmg/ddu121.
Kienesberger, P. C., Oberer, M., Lass, A., Zechner, R. (2009). Mammalian patatin domain containingproteins: a family with diverse lipolytic activities involved in multiple biological functions. Journal of lipid research, 50 (Supplement), 63–68. doi: 10.1194/jlr.R800082-JLR200
Wu, J. T., Liu, S. S., Xie, X. J., Liu, Q., Xin, Y. N., Xuan, S. Y. (2020). Independent and jointcorrelation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease. Lipids in Health and Disease, 19(1), 1–7. doi: 10.1186/s12944-020-01207-9.
Mantovani, A., Chiara, Z. (2020). PNPLA3 gene and kidney disease. Exploration of Medicine, 1,42–50. doi: 10.37349/emed.2020.00004.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M.,& Kahan, T.(2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, 39(33), 3021–3104. doi: 10.1093/eurheartj/ ehy339.
Trepo, E., Romeo, S., Zucman-Rossi, J., & Nahon, P. (2016). PNPLA3 gene in liver diseases.Journal of hepatology, 65(2), 399–412. doi: 10.1016/j.jhep.2016.03.011.
Bruschi, F. V., Claudel, T., Tardelli, M., Caligiuri, A., Stulnig, T. M., Marra, F., Trauner, M.(2017). The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology, 65(6), 1875–1890. doi: 10.1002/hep.29041.
Johansson, L. E., Johansson, L. M., Danielsson, P., Norgren, S., Johansson, S., Marcus, C.,Ridderstrale, M. (2009). Genetic variance in the adiponutrin gene family and childhood obesity. PLoS One, 4(4). doi: 10.1371/journal.pone.0005327.
Qadri, S., Lallukka-Bruck, S., Luukkonen, P. K., Zhou, Y., Gastaldelli, A., Orho-Melander, M. &Hakkarainen, A. (2020). The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver International, 40(9), 2128–2138. doi: 10.1111/liv.14507.
Quiroga, A. D., Lehner, R. (2018). Pharmacological intervention of liver triacylglycerol lipolysis: The good, the bad and the ugly. Biochemical pharmacology, 155, 233–241. doi: 10.1016/j.bcp.2018.07.005.
Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).
The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.
Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.